A device smaller than a seed, powered by invisible fields
In the laboratories of Abu Dhabi, a partnership between two research institutions has produced something that quietly defies the scale of human suffering it aims to address: a wireless device smaller than a seed, injectable through a standard needle, capable of sending electrical signals that retrain misbehaving nerves. For the millions living with Parkinson's disease and chronic nerve pain, whose options have long meant either enduring symptoms or submitting to invasive surgery, this technology represents a rethinking of what access to relief might look like. It is not yet approved for human use, but it has passed the scrutiny of peer review and preclinical testing — a small object carrying the weight of considerable human hope.
- Millions of Parkinson's patients face a painful choice between worsening symptoms and high-risk surgical implants that carry infection, battery failure, and mechanical breakdown.
- A seed-sized wireless device, injected beneath the skin near a target nerve, now challenges that binary by delivering precise electrical stimulation without a single incision.
- Powered by external electromagnetic fields rather than an internal battery, the device allows physicians to personalize stimulation in real time — something fixed implants cannot offer.
- Preclinical testing confirmed consistent, reliable nerve stimulation, clearing a critical threshold on the long road toward regulatory approval and human trials.
- Researchers frame the breakthrough not only as a clinical advance but as an equity issue — simpler, safer neuromodulation could reach patients who today refuse treatment because surgery feels too dangerous or too costly.
In a laboratory in Abu Dhabi, researchers have built something that fits inside the eye of a needle — a wireless device no larger than a seed that could change how medicine treats the tremors and movement disorders of Parkinson's disease and other chronic nerve conditions. The work, a collaboration between Cleveland Clinic Abu Dhabi and NYU Abu Dhabi, has been published in Science Advances, the peer-reviewed journal of the American Association for the Advancement of Science.
What separates this device from existing treatments is its radical simplicity. Managing Parkinson's today means medication, physical therapy, or Deep Brain Stimulation — a procedure requiring surgically implanted hardware that runs on batteries, risks infection, and eventually demands replacement surgery. The injectable device bypasses all of that. A standard needle delivers it to the target nerve, standard imaging can locate it inside the body, and it never needs to be removed or replaced.
Power comes wirelessly, drawn from electromagnetic fields applied externally by physicians. That architecture eliminates the battery countdown and allows doctors to adjust stimulation strength and timing to each patient's changing needs. Senior author Khalil Ramadi described the ambition plainly: to make these therapies simpler, safer, and more accessible without sacrificing precise control over nerve activity.
In preclinical testing, the device delivered electrical stimulation consistently and without failure — the kind of reliability that human application would demand. The implications extend beyond clinical performance. Many patients today forgo surgery not because it wouldn't help, but because the risks feel too high. A less invasive path could bring relief to those who have been quietly waiting for one.
Regulatory approval remains ahead, and the distance between a laboratory result and a clinical therapy is never short. But the device exists, it has been tested, and the science behind it has withstood scrutiny. A technology that once belonged to science fiction is now waiting at the threshold of medicine.
In a laboratory in Abu Dhabi, researchers have engineered something that fits in the eye of a needle—a wireless device no larger than a seed that could reshape how doctors treat the tremors, stiffness, and movement disorders that plague millions of people with Parkinson's disease and other chronic nerve conditions.
The device is the product of a partnership between Cleveland Clinic Abu Dhabi and NYU Abu Dhabi. Once injected beneath the skin near a target nerve, it begins sending electrical signals designed to retrain how that nerve behaves, offering patients a path to pain relief without the burden of traditional surgery. The work has been published in Science Advances, the peer-reviewed journal of the American Association for the Advancement of Science, lending it the weight of rigorous scientific scrutiny.
What makes this approach fundamentally different from existing treatments is its simplicity. Current options for managing Parkinson's—a progressive neurological disease caused by the death of brain cells that produce dopamine—range from medication to physical therapy to more invasive procedures like Deep Brain Stimulation, which requires surgical implantation of bulky hardware. Those implanted devices carry real risks: they rely on batteries that eventually fail and need replacement through additional surgery, they can become infected, and they can mechanically break down. The injectable device sidesteps all of this. A standard needle delivers it. Standard imaging—ultrasound or CT scans—can locate it inside the body. And it requires no surgical removal or replacement.
The device is powered wirelessly, drawing energy from electromagnetic fields applied externally by physicians. This wireless architecture means no battery to deplete, no ticking clock counting down to the next operation. Instead, doctors can adjust the strength and timing of the electrical stimulation to match each patient's specific needs, personalizing treatment in ways that fixed implants cannot. Khalil Ramadi, the study's senior author and an assistant professor of bioengineering at NYU Abu Dhabi and NYU Tandon, framed the innovation in terms of access and safety: "By creating a device that can be injected rather than surgically implanted, we are making these therapies simpler, safer, and more accessible, while still maintaining precise control over nerve activity."
In laboratory and preclinical testing, the device has demonstrated the precision and reliability that would be required for human use. It consistently delivered electrical stimulation to target nerves without drift or failure. The implications are substantial. Parkinson's disease affects millions worldwide, and the condition worsens over time as more dopamine-producing neurons die. Patients lose the ability to move fluidly, develop tremors, and experience cognitive decline. Current treatments help but do not halt the underlying disease. A less invasive, more accessible neuromodulation tool could extend relief to patients who today avoid surgery because the risks feel too high or the recovery too burdensome.
Dr. Sawsan Abdel-Razig, chief academic officer at Cleveland Clinic Abu Dhabi, emphasized the collaborative nature of the work and what it signals about the future of medical innovation in the region. The partnership between the two institutions brought together expertise in bioengineering, clinical medicine, and translational research—the bridge between laboratory discovery and bedside application. That kind of multidisciplinary collaboration, she suggested, is how safer, less invasive therapies move from concept to clinic.
The device is not yet approved for human use. Regulatory pathways remain ahead. But the research is clear: a technology once confined to the realm of science fiction—a wireless implant smaller than a seed, powered by invisible electromagnetic fields, capable of teaching nerves to behave differently—is now real, tested, and waiting for the next phase of its journey into medicine.
Notable Quotes
By creating a device that can be injected rather than surgically implanted, we are making these therapies simpler, safer, and more accessible, while still maintaining precise control over nerve activity.— Khalil Ramadi, assistant professor of bioengineering at NYU Abu Dhabi and NYU Tandon
This collaboration reflects our commitment to advancing innovative, clinically relevant research that translates into meaningful improvements in patient care.— Dr. Sawsan Abdel-Razig, chief academic officer at Cleveland Clinic Abu Dhabi
The Hearth Conversation Another angle on the story
Why does size matter so much here? Couldn't doctors already implant smaller devices?
The size matters because it changes how the device gets into the body. A surgical implant requires an operating room, anesthesia, an incision, stitches, recovery time. A needle injection happens in a clinic. You walk in, get the injection, walk out. That's a massive difference for patients.
And the wireless power—how does that actually work? Is it safe to have electromagnetic fields running through your body?
The electromagnetic fields are applied externally, from outside the body, similar to how wireless charging works on your phone. The device receives that energy and converts it into electrical pulses for the nerve. It's not constant—doctors control it. And the fields used are within safety limits that medical imaging already uses routinely.
What happens if the device fails or the patient wants it removed?
That's one of the elegant parts. Because it's injected, not surgically implanted, removal is theoretically simpler than extracting a traditional implant. And because there's no battery, there's no ticking clock forcing replacement surgery. If something goes wrong, you're not locked into a device that needs surgical extraction.
Who benefits most from this? Is it only Parkinson's patients?
Parkinson's is the headline case because it's so prevalent and current treatments are limited. But the underlying principle—using electrical signals to modulate nerve behavior—applies to many chronic pain conditions and neurological disorders. The real beneficiary is anyone currently avoiding surgery because the risks feel too high.
When will patients actually be able to use this?
That's the open question. The science is proven. The next step is regulatory approval and human trials. If those go well, we're probably looking at several years before it's available in clinics. But the pathway is clear now.